The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally resectable advanced gastric cancer: Survival results of COMPASS.
 
Takaki Yoshikawa
Honoraria - Abbott Laboratories; Chugai Pharma; Covidien; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Ono Pharmaceutical; Secom Medical System; Taiho Pharmaceutical
Consulting or Advisory Role - Novartis
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Kazuaki Tanabe
No Relationships to Disclose
 
Kazuhiro Nishikawa
Honoraria - Ajinomoto; Chugai Pharma; Taiho Pharmaceutical; TERUMO; Tsumura & Co.; Yakult Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Kazumasa Fujitani
No Relationships to Disclose
 
Yuichi Ito
No Relationships to Disclose
 
Takanori Matsui
Honoraria - Chugai Pharma
 
Tsutomu Hayashi
No Relationships to Disclose
 
Toru Aoyama
Honoraria - Taiho Pharmaceutical; Takeda
 
Haruhiko Cho
Honoraria - Novartis; Pfizer
 
Satoshi Morita
Honoraria - Bristol-Myers Squibb Japan; Taiho Pharmaceutical
 
Yumi Miyashita
No Relationships to Disclose
 
Akira Tsuburaya
No Relationships to Disclose
 
Junichi Sakamoto
Honoraria - Takeda